Literature DB >> 2010685

A polymorphism in a region with enhancer activity in the second intron of the human apolipoprotein B gene.

B Levy-Wilson1, L Soria, E H Ludwig, M Argyres, A R Brooks, B D Blackhart, W Friedl, B J McCarthy.   

Abstract

A 443-base pair fragment (+622 to +1064) from the second intron of the human apolipoprotein B gene was shown to contain a tissue-specific enhancer when placed in front of an apolipoprotein B promoter-chloramphenicol acetyltransferase construct in transfection experiments. To identify potential regulatory mutations in this region of the gene, DNA from various subjects was examined for the presence of point mutations by means of chemical cleavage of mismatched heteroduplexes. An A----G substitution within the second intron of the gene at position +722 was identified in three unrelated subjects and confirmed by DNA sequencing. Although the base substitution was contained within a nuclear protein-binding site, as determined by DNase I footprinting, it did not appear to affect the protein/DNA interaction in its vicinity, as shown by gel retardation experiments. The single base substitution at position +722 abolishes a StyI restriction site, thus creating a StyI polymorphism. Using allele-specific oligonucleotides, we screened the DNA of 172 subjects for the presence of this polymorphism: two other subjects carrying the polymorphism were found. In each of the five unrelated subjects, the polymorphism was associated with the same haplotype.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010685

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  2 in total

1.  Hepatocyte nuclear factor 1 and C/EBP are essential for the activity of the human apolipoprotein B gene second-intron enhancer.

Authors:  A R Brooks; B Levy-Wilson
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

2.  Modification of the apolipoprotein B gene in HepG2 cells by gene targeting.

Authors:  R V Farese; L M Flynn; S G Young
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.